By Caroline Helwick
San Francisco—In a single-center study of elderly patients with advanced pancreatic cancer, reductions in the dose of gemcitabine plus nab-paclitaxel resulted in better tolerability than standard dosing, without compromising survival.
OCTOBER 8, 2019